Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
Authors:
Open Access
- 28 March 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (13) , 10419-10425
Abstract
Despite ongoing efforts to employ structure-based methods to discover targeted protein degraders (TPD), the prevailing strategy continues to be the synthesis of a focused set of heterobifunctional compounds and screening them for target protein degradation. Here we used a fluorescence based live cell imaging screen to identify degraders that target exon 14 skipped hepatocyte growth factor receptor (MET). MET is a known oncogenic driver. MET exon 14 skipping mutations (METex14Δ) are found in lung cancers and result in the loss of a degron that is required for E3-ligase recognition and subsequent ubiquitination, prolonging the half-life and oncogenicity of MET. Since proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that promote target degradation by the proteosome, we sought to restore degradation of MET lost with METex14Δ using a MET-targeting PROTAC. We generated a library of sixty PROTACs of which 37 used the MET inhibitor capmatinib as the protein of interest targeting ligand. We screened this PROTAC library for targeted degradation of METex14Δ-GFP using live cell imaging. We benchmarked the MET-targeting PROTACs to that of a previously reported MET-targeting PROTAC, SJF8240. Curve fitting live cell imaging data affords determination of time required to degrade 50% of the target protein (DT50), which was used in determining structure activity relationships. A promising candidate, 48-284, identified from the screen, exhibited classic PROTAC characteristics, was >15-fold more potent than SJF8240, had fewer off targets compared to SJF8240, and degraded MET in multiple cell lines.Keywords
All Related Versions
Funding Information
- University of Nebraska-Lincoln (TSG26784)
- National Institutes of Health (CA197999)
- National Institutes of Health (CA251151)
- National Institutes of Health (CA260749)
- National Institutes of Health (GM121316)
- National Institutes of Health (CA036727)
- National Institutes of Health (R01NS101721)
- National Cancer Institute (R21 CA251923)
- Mayo Clinic
This publication has 27 references indexed in Scilit:
- Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted CancerJournal of Medicinal Chemistry, 2024
- Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterationsActa Pharmaceutica Sinica B, 2023
- 3‐phosphoinositide‐dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signalingFEBS Letters, 2021
- Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclaxBioorganic & Medicinal Chemistry Letters, 2021
- Exploring Targeted Degradation Strategy for Oncogenic KRASG12CCell Chemical Biology, 2020
- Selective degradation of CDK6 by a palbociclib based PROTACBioorganic & Medicinal Chemistry Letters, 2019
- Lessons in PROTAC Design from Selective Degradation with a Promiscuous WarheadCell Chemical Biology, 2018
- The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case StudyCell Chemical Biology, 2018
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?Journal of Medicinal Chemistry, 2017
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletionBiochemical and Biophysical Research Communications, 2010